Rossari Biotech (ROSSARI) Panoramica del titolo
Rossari Biotech Limited si occupa della produzione e della vendita di specialità chimiche in India e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 5/6 |
| Crescita futura | 1/6 |
| Prestazioni passate | 3/6 |
| Salute finanziaria | 4/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
Non sono stati rilevati rischi per ROSSARI dai nostri controlli di rischio.
ROSSARI Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Rossari Biotech Limited
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | ₹513.95 |
| Massimo di 52 settimane | ₹690.30 |
| Minimo di 52 settimane | ₹375.00 |
| Beta | 0.55 |
| Variazione di 1 mese | -0.94% |
| Variazione a 3 mesi | -5.52% |
| Variazione di 1 anno | -20.69% |
| Variazione a 3 anni | -39.35% |
| Variazione a 5 anni | -62.29% |
| Variazione dall'IPO | -30.70% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Jun 30
ROSSARI: New R&D Relocation Will Support Stronger Long-Term Prospects
Analysts have reduced their fair value estimate for Rossari Biotech from ₹813 to ₹637. This change reflects an updated view that combines a slightly lower discount rate and higher projected revenue growth with expectations of a lower profit margin and a reduced future P/E multiple.
Aggiornamento narrativa • Jun 16
ROSSARI: Navi Mumbai R And D Shift Will Drive Future Upside
Analysts have kept Rossari Biotech's fair value estimate steady at ₹601.75, with only minor adjustments to assumptions around the discount rate, revenue growth, profit margin and future P/E that do not materially change their overall valuation view. What's in the News Board meeting scheduled for May 27, 2026, at 16:00 IST to consider the re appointment of Ms. Esha Padmanabhan Achan as a Non Executive Independent Director and the grant of options under the Rossari Employee Stock Option Plan 2019.Aggiornamento narrativa • Jun 01
ROSSARI: New Navi Mumbai R And D Move Will Support Future Upside
Analysts have maintained their fair value estimate for Rossari Biotech at ₹601.75, with only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions, resulting in an unchanged price target. What's in the News A board meeting is scheduled for May 27, 2026 at 16:00 IST to consider the reappointment of Ms. Esha Padmanabhan Achan as a non-executive independent director and to evaluate the grant of options under the Rossari Employee Stock Option Plan 2019.Recent updates
Aggiornamento narrativa • Jun 30
ROSSARI: New R&D Relocation Will Support Stronger Long-Term Prospects
Analysts have reduced their fair value estimate for Rossari Biotech from ₹813 to ₹637. This change reflects an updated view that combines a slightly lower discount rate and higher projected revenue growth with expectations of a lower profit margin and a reduced future P/E multiple.Aggiornamento narrativa • Jun 16
ROSSARI: Navi Mumbai R And D Shift Will Drive Future Upside
Analysts have kept Rossari Biotech's fair value estimate steady at ₹601.75, with only minor adjustments to assumptions around the discount rate, revenue growth, profit margin and future P/E that do not materially change their overall valuation view. What's in the News Board meeting scheduled for May 27, 2026, at 16:00 IST to consider the re appointment of Ms. Esha Padmanabhan Achan as a Non Executive Independent Director and the grant of options under the Rossari Employee Stock Option Plan 2019.Aggiornamento narrativa • Jun 01
ROSSARI: New Navi Mumbai R And D Move Will Support Future Upside
Analysts have maintained their fair value estimate for Rossari Biotech at ₹601.75, with only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions, resulting in an unchanged price target. What's in the News A board meeting is scheduled for May 27, 2026 at 16:00 IST to consider the reappointment of Ms. Esha Padmanabhan Achan as a non-executive independent director and to evaluate the grant of options under the Rossari Employee Stock Option Plan 2019.Aggiornamento narrativa • May 14
ROSSARI: New R&D Consolidation And Board Decisions Will Drive Future Upside
Analysts now set a revised price target for Rossari Biotech at ₹601.75, down from ₹635.50, reflecting slightly softer assumptions around revenue growth, profit margins, and future P/E multiples. What's in the News Rossari Biotech has set up a new Research and Development Facility at Ellora Olearise, A-786, 06th Floor, Khairane MIDC, Koparkhairane, Navi Mumbai 400 710.Articolo di analisi • May 04
Rossari Biotech's (NSE:ROSSARI) Profits Appear To Have Quality Issues
Rossari Biotech Limited's ( NSE:ROSSARI ) stock didn't jump after it announced some healthy earnings. We did some...Aggiornamento narrativa • Apr 25
ROSSARI: Upcoming Board Meeting And Dividend Decision Will Shape Future Upside Potential
Analysts have kept Rossari Biotech's fair value estimate steady at ₹635.5, with only small technical tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, so the headline price target remains unchanged. What's in the News Board meeting scheduled for April 27, 2026, to review and approve audited standalone and consolidated financial statements for the quarter and financial year ended March 31, 2026 (company filing).Aggiornamento narrativa • Apr 09
ROSSARI: Greenfield Expansion And Subsidiary Restructuring Will Shape Future Upside Potential
Analysts have kept Rossari Biotech's fair value estimate steady at ₹635.50, citing only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions rather than any major shift in the core outlook. What's in the News A board meeting is scheduled on January 17, 2026 at 12:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Aggiornamento narrativa • Mar 26
ROSSARI: Greenfield Capacity Expansion Will Support Future Upside Potential
Analysts have maintained the fair value estimate for Rossari Biotech at ₹635.5, making only minor technical adjustments to assumptions such as the discount rate, revenue growth, profit margin, and future P/E, which result in an essentially unchanged price target view. What's in the News A board meeting is scheduled for January 17, 2026, at 12:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Aggiornamento narrativa • Mar 08
ROSSARI: Greenfield Expansion And Subsidiary Buildout Will Support Future Upside
Analysts have maintained Rossari Biotech's fair value estimate at ₹635.50, making only minor adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E to reflect updated modelling assumptions rather than a change in conviction. What's in the News A board meeting is scheduled on Jan 17, 2026 at 12:30 Indian Standard Time to consider unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Aggiornamento narrativa • Feb 22
ROSSARI: Greenfield Capacity Expansion Will Support Future Upside Potential
Analysts have kept their fair value estimate for Rossari Biotech steady at ₹635.5, with the unchanged price target reflecting only marginal tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Board meeting scheduled for January 17, 2026, to review unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and to consider several key corporate actions, including new projects and asset changes (company filing).Aggiornamento narrativa • Feb 05
ROSSARI: Greenfield Expansion And Subsidiary Reshaping Will Support Future Upside Potential
Analysts have trimmed their fair value estimate for Rossari Biotech slightly from ₹637.33 to ₹635.50, reflecting updated assumptions around discount rate, profit margin and future P/E, while keeping revenue growth expectations broadly aligned with prior views. What's in the News Board meeting scheduled on Jan 17, 2026 at 12:30 IST to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, and to consider several corporate actions (company filing).Aggiornamento narrativa • Jan 22
ROSSARI: International Capacity Expansion Plans Will Drive Future Upside Potential
Analysts have revised their price target on Rossari Biotech lower from ₹795.75 to about ₹637.33, citing updated assumptions on the discount rate, revenue growth, profit margins and future P/E as key drivers of the change. What's in the News A board meeting is scheduled on Jan 17, 2026, to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Articolo di analisi • Jan 22
Analysts Have Lowered Expectations For Rossari Biotech Limited (NSE:ROSSARI) After Its Latest Results
Shareholders might have noticed that Rossari Biotech Limited ( NSE:ROSSARI ) filed its third-quarter result this time...Aggiornamento narrativa • Jan 08
ROSSARI: International Capacity Expansions Will Drive Future Upside Potential
Analysts have kept their fair value estimate for Rossari Biotech steady at ₹795.75, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E to better reflect current expectations. What's in the News A board meeting is scheduled on December 18, 2025 at 10:30 a.m. Indian Standard Time to consider and approve the incorporation of a wholly owned subsidiary in the Republic of Singapore (company filing).Aggiornamento narrativa • Dec 21
ROSSARI: Planned Singapore Subsidiary Will Drive Future International Expansion Upside
Analysts have reaffirmed their price target on Rossari Biotech at ₹795.75 per share, with only marginal tweaks to underlying assumptions such as discount rate, long term revenue growth, profit margin, and future P E multiple, reflecting a largely unchanged outlook on the company’s earnings trajectory and risk profile. What's in the News Board to meet on December 18, 2025, to consider incorporating a wholly owned subsidiary in the Republic of Singapore (Board Meeting) Successfully commissioned an additional 20,000 MTPA capacity at the Dahej facility, taking total installed capacity to 1,52,500 MTPA (Business Expansions) Commissioned 15,000 MTPA ethoxylation capacity at Unitop in Phase 1 of a 30,000 MTPA plan, with Phase 2 expected by the third quarter of fiscal 2026 (Business Expansions) Board approved an investment of up to USD 8 million in Rossari International Limited Company in Saudi Arabia to evaluate and assess expansion plans in international markets (Business Expansions) Board meeting scheduled on October 15, 2025, to approve unaudited financial results for the quarter and half year ended September 30, 2025 (Board Meeting) Valuation Changes The consensus analyst price target remains unchanged at ₹795.75 per share, indicating a stable fair value assessment.Aggiornamento narrativa • Dec 06
ROSSARI: Capacity Expansion And Saudi Subsidiary Investment Will Drive Future Upside
Narrative Update on Rossari Biotech Analysts have maintained their price target for Rossari Biotech at ₹795.75, citing largely unchanged assumptions around discount rate, revenue growth, profit margins, and future valuation multiples. Taken together, these factors suggest limited change in the company’s fundamental outlook.Aggiornamento narrativa • Nov 22
ROSSARI: Additional Capacity Expansions Will Unlock Global Opportunities Ahead
Narrative Update on Rossari Biotech Analysts have maintained their fair value estimate for Rossari Biotech at ₹795.75, citing minimal changes in key financial assumptions and continued confidence in the company’s outlook. What's in the News Successfully commissioned an additional 20,000 MTPA capacity at the Dahej facility during the quarter, bringing total installed capacity to 1,52,500 MTPA.Aggiornamento narrativa • Nov 04
ROSSARI: New Expansion Projects Will Drive Global Market Penetration
Narrative Update on Rossari Biotech: Analyst Price Target Revision Analysts have revised Rossari Biotech’s fair value estimate downward from ₹826.67 to ₹795.75, citing slightly lower expectations for revenue growth and profit margins. What's in the News The company commissioned an additional 20,000 MTPA capacity at its Dahej facility, bringing total installed capacity to 1,52,500 MTPA (Key Developments).Articolo di analisi • Oct 28
We Think That There Are More Issues For Rossari Biotech (NSE:ROSSARI) Than Just Sluggish Earnings
Rossari Biotech Limited's ( NSE:ROSSARI ) recent weak earnings report didn't cause a big stock movement. Our analysis...Articolo di analisi • Jun 24
Here's Why Rossari Biotech Limited's (NSE:ROSSARI) CEO Compensation Is The Least Of Shareholders Concerns
Key Insights Rossari Biotech will host its Annual General Meeting on 30th of June Total pay for CEO Sunil Chari...
Nuova narrativa • Feb 10
Eco-friendly Solutions And New Capacities Will Strengthen Future Prospects
Strategic investments in capacity expansion and innovation in eco-friendly solutions are expected to drive revenue growth in domestic and international markets.Articolo di analisi • Aug 17
Why We Think Rossari Biotech Limited's (NSE:ROSSARI) CEO Compensation Is Not Excessive At All
Key Insights Rossari Biotech's Annual General Meeting to take place on 23rd of August Salary of ₹12.1m is part of CEO...Articolo di analisi • Jun 14
Is Rossari Biotech (NSE:ROSSARI) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • May 07
Rossari Biotech's (NSE:ROSSARI) Solid Profits Have Weak Fundamentals
Investors were disappointed with Rossari Biotech Limited's ( NSE:ROSSARI ) earnings, despite the strong profit numbers...Articolo di analisi • May 03
Analyst Estimates: Here's What Brokers Think Of Rossari Biotech Limited (NSE:ROSSARI) After Its Annual Report
Last week, you might have seen that Rossari Biotech Limited ( NSE:ROSSARI ) released its full-year result to the...Articolo di analisi • Feb 10
One Analyst Just Shaved Their Rossari Biotech Limited (NSE:ROSSARI) Forecasts Dramatically
The analyst covering Rossari Biotech Limited ( NSE:ROSSARI ) delivered a dose of negativity to shareholders today, by...Articolo di analisi • Sep 23
Returns On Capital At Rossari Biotech (NSE:ROSSARI) Paint A Concerning Picture
What trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...Articolo di analisi • Apr 06
Returns On Capital Signal Tricky Times Ahead For Rossari Biotech (NSE:ROSSARI)
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Articolo di analisi • Feb 19
Need To Know: Analysts Are Much More Bullish On Rossari Biotech Limited (NSE:ROSSARI) Revenues
Rossari Biotech Limited ( NSE:ROSSARI ) shareholders will have a reason to smile today, with the analysts making...Articolo di analisi • Feb 17
Rossari Biotech Limited Just Beat Revenue Estimates By 6.8%
Shareholders might have noticed that Rossari Biotech Limited ( NSE:ROSSARI ) filed its third-quarter result this time...Articolo di analisi • Feb 10
I Ran A Stock Scan For Earnings Growth And Rossari Biotech (NSE:ROSSARI) Passed With Ease
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...Articolo di analisi • Nov 24
Capital Allocation Trends At Rossari Biotech (NSE:ROSSARI) Aren't Ideal
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Articolo di analisi • Oct 12
With EPS Growth And More, Rossari Biotech (NSE:ROSSARI) Is Interesting
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...Rendimenti per gli azionisti
| ROSSARI | IN Chemicals | IN Mercato | |
|---|---|---|---|
| 7D | 1.9% | 1.7% | 1.3% |
| 1Y | -20.7% | 1.3% | 5.9% |
Ritorno vs Industria: ROSSARI ha avuto una performance inferiore rispetto al Indian Chemicals che ha registrato un rendimento 1.3 % nell'ultimo anno.
Rendimento vs Mercato: ROSSARI ha avuto una performance inferiore al mercato Indian che ha registrato un rendimento 5.9 % nell'ultimo anno.
Volatilità dei prezzi
| ROSSARI volatility | |
|---|---|
| ROSSARI Average Weekly Movement | 5.1% |
| Chemicals Industry Average Movement | 6.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.7% |
Prezzo delle azioni stabile: ROSSARI non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Indian.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di ROSSARI è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1997 | 585 | Sunil Chari | www.rossari.com |
Rossari Biotech Limited si occupa della produzione e della vendita di specialità chimiche in India e a livello internazionale. Offre saponi e detergenti, inchiostri, vernici e rivestimenti, ceramiche e piastrelle, pasta e carta, cemento, additivi per le prestazioni e soluzioni per il trattamento delle acque. L'azienda fornisce anche specialità chimiche per il settore tessile, come cotone, poliestere, acrilico, lana, seta, nylon, finissaggi funzionali, denim, stampa e soluzioni sostenibili; e prodotti per la cura degli animali domestici, che includono shampoo naturali, polveri, deodoranti, spray, creme e liquidi per il lavaggio dei pavimenti con i marchi Lozalo, Hunger Fills e Sniffy.
Rossari Biotech Limited Riepilogo dei fondamenti
| ROSSARI statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | ₹28.47b |
| Utili (TTM) | ₹1.51b |
| Ricavi(TTM) | ₹25.50b |
18.9x
Rapporto P/E1.1x
Rapporto P/SROSSARI è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| ROSSARI Conto economico (TTM) | |
|---|---|
| Ricavi | ₹25.50b |
| Costo del fatturato | ₹17.97b |
| Profitto lordo | ₹7.53b |
| Altre spese | ₹6.02b |
| Utili | ₹1.51b |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 27.21 |
| Margine lordo | 29.53% |
| Margine di profitto netto | 5.91% |
| Rapporto debito/patrimonio netto | 32.7% |
Come si è comportato ROSSARI nel lungo periodo?
Vedi performance storica e confrontoDividendi
0.1%
Rendimento attuale del dividendo2%
Rapporto di remunerazioneROSSARI paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di ROSSARI| Rossari Biotech date dei dividendi | |
|---|---|
| Data di stacco del dividendo | Jul 10 2026 |
| Data di pagamento dei dividendi | Aug 19 2026 |
| Giorni fino al dividendo Ex | 30 days |
| Giorni prima della data di pagamento dei dividendi | 10 days |
ROSSARI paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di ROSSARIAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/08 22:12 |
| Prezzo dell'azione a fine giornata | 2026/08/07 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Rossari Biotech Limited è coperta da 5 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Nitesh Dhoot | Anand Rathi Shares and Stock Brokers Limited |
| Abhishek Navalgund | Centrum Broking Limited |